Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

Dexamethasone

Dexamthasone 40mg every day, days -5 to -1 only will be given.

DRUG

Cyclophosphamide

A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.

DRUG

Melphalan

Melphalan will be given as a single dose of 140mg/m2 on day -1. Subject weighing more than 60kg will be dosed according to their calculated body weight.Melphalan will be diluted in normal saline(0.9%NaCl) to a concentration of 1.5mg/ml. A dose of 140mg/m2 will be administered intravenously over a period \<or= 20 minutes on day -1.

DRUG

Fludarabine

dose of 1.0mg/m2 on days -8,-5,-2.

DRUG

Bortezomide

A dose of 1.0mg/m2 will be given as a bolus dose on day-8, day-5 and day-2 as per standard practice

PROCEDURE

Leukapheresis

On day 0 to collect donor cells for NK cell isolation

DRUG

Interleukin

2 at 3x10x6 IU on days +1 to 13.

PROCEDURE

Infusion #1

Infusion of donor NK Cells #1 on day 0

PROCEDURE

Leukapheresis #2

on day +2

PROCEDURE

Infusion #2

on day +2

PROCEDURE

Auto Graft

on day +14

Trial Locations (1)

72205

University of Arkansas for Medical Sciences/MIRT, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER

NCT00089453 - Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant | Biotech Hunter | Biotech Hunter